Skip to Main Content

Author Details

Rosalie C Sears
Oregon Health and Science University
1987
112
49
PMIDPaper TitleJournal TitlePublished Year
36912080The ubiquitin-specific protease USP36 SUMOylates EXOSC10 and promotes the nucleolar RNA exosome function in rRNA processing.Nucleic Acids Res2023
37704631MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer.Nat Commun2023
36912080The ubiquitin-specific protease USP36 SUMOylates EXOSC10 and promotes the nucleolar RNA exosome function in rRNA processing.Nucleic Acids Res2023
37089813Deletion of the mRNA stability factor <i>ELAVL1</i> (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity.NAR Cancer2023
36778343Robust biomarker discovery through multiplatform multiplex image analysis of breast cancer clinical cohorts.bioRxiv2023
37406115Melanoma-intrinsic NR2F6 activity regulates antitumor immunity.Sci Adv2023
37704631MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer.Nat Commun2023
37089813Deletion of the mRNA stability factor <i>ELAVL1</i> (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity.NAR Cancer2023
37406115Melanoma-intrinsic NR2F6 activity regulates antitumor immunity.Sci Adv2023
36778343Robust biomarker discovery through multiplatform multiplex image analysis of breast cancer clinical cohorts.bioRxiv2023
35456547Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer.Pharmaceutics2022
35456547Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer.Pharmaceutics2022
35703534The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.Mol Cell Biol2022
35819261Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.Cancer Res2022
35380701T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62.Mol Cancer Res2022
35406624HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms.Cancers (Basel)2022
35380701T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62.Mol Cancer Res2022
35406624HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms.Cancers (Basel)2022
35703534The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.Mol Cell Biol2022
35819261Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.Cancer Res2022
33972797Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.Nat Chem Biol2021
34019287Detection of Post-translational Modifications on MYC.Methods Mol Biol2021
33972797Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.Nat Chem Biol2021
34178666Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy.Front Oncol2021
33854232AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.Nature2021
33852194The deubiquitinase USP36 promotes snoRNP group SUMOylation and is essential for ribosome biogenesis.EMBO Rep2021
34226710High-content single-cell combinatorial indexing.Nat Biotechnol2021
34222745<i>Ex Vivo</i> Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.Annu Rev Cancer Biol2021
33953176Loss of Ambra1 promotes melanoma growth and invasion.Nat Commun2021
33727309Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.Cancer Discov2021
34036232Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma.JCO Precis Oncol2021
34399819Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.Cancer Metab2021
33854232AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity.Nature2021
33852194The deubiquitinase USP36 promotes snoRNP group SUMOylation and is essential for ribosome biogenesis.EMBO Rep2021
33727309Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.Cancer Discov2021
34399819Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.Cancer Metab2021
34222745<i>Ex Vivo</i> Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.Annu Rev Cancer Biol2021
34019287Detection of Post-translational Modifications on MYC.Methods Mol Biol2021
34178666Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy.Front Oncol2021
34036232Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma.JCO Precis Oncol2021
33953176Loss of Ambra1 promotes melanoma growth and invasion.Nat Commun2021
34226710High-content single-cell combinatorial indexing.Nat Biotechnol2021
32434218Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer.J Exp Med2020
32434218Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer.J Exp Med2020
32300594PIN1 Provides Dynamic Control of MYC in Response to Extrinsic Signals.Front Cell Dev Biol2020
32238397Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC.Cancer Discov2020
31822503Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.J Biol Chem2020
31763993Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.J Clin Invest2020
32822815Hypoxia: Friend or Foe for drug delivery in Pancreatic Cancer.Cancer Lett2020
32624198Select Stabilization of a Tumor-Suppressive PP2A Heterotrimer.Trends Pharmacol Sci2020
  • 1 - 50 of 224

Recommended Authors

University of Toronto
Career Start Year 2014
Number of shared co-authors 1
Van Andel Institute
Career Start Year 2011
Number of shared co-authors 1
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Princess Margaret Cancer Center
Career Start Year 2009
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Institute for Research in Immunology and Cancer (IRIC)
Career Start Year 2004
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 2000
Number of shared co-authors 0
Integrated Graduate School of Medicine, University of Yamanashi
Career Start Year 2000
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 4
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 3
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 4
Case Western Reserve University School of Medicine
Career Start Year 1993
Number of shared co-authors 5
Cancer Research UK Beatson Institute
Career Start Year 1993
Number of shared co-authors 1
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 3
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 6
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 13
University of Toronto
Career Start Year 1990
Number of shared co-authors 3
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 8
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 10
British Columbia Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 15
Amsterdam University Medical Center
Career Start Year 1989
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 3
University of Toronto
Career Start Year 1988
Number of shared co-authors 4
University of California San Diego
Career Start Year 1988
Number of shared co-authors 5
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 3
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 7
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 11
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 11
Johns Hopkins University School of Medicine
Career Start Year 1978
Number of shared co-authors 6

Collaborators

TFF Pharmaceuticals, Inc.
Co-authored papers 5
The University of Michigan Medical School ann arbor
Co-authored papers 5
Oregon Health and Science University
Co-authored papers 5
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
University of Michigan ann arbor
Co-authored papers 3
Oregon Health & Science University School of Medicine
Co-authored papers 3
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 3
Dana-Farber Cancer Institute
Co-authored papers 3
Co-authored papers 3
Cranfield University
Co-authored papers 3
Atux Iskay LLC
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Duke University Medical Center
Co-authored papers 3
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Oregon Health & Science University Hospital.
Co-authored papers 2
Oregon Health and Science University
Co-authored papers 2
Lombardi Comprehensive Cancer Center, Georgetown University
Co-authored papers 2
Co-authored papers 2
University of Navarra
Co-authored papers 2
University of Colorado Anschutz Medical Campus
Co-authored papers 2
Oregon Health & Science University
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Oregon Health and Science University
Co-authored papers 2
Co-authored papers 2
Oregon Health Sciences University
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2